Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Richard C. Centore
Observed names:
R. Centore,
Richard C Centore,
Richard Centore,
Richard C. Centore
Observed institutions:
Harvard University,
University of Massachusetts Amherst,
Massachusetts General Hospital,
Constellation Pharmaceuticals (United States),
Foghorn Therapeutics (United States)
OpenAlex ID:
A5079460736
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
2020
·
Richard C. Centore
, Gabriel J. Sandoval
, et al.
·
Trends in Genetics
·
394
PDF
TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA
2011
·
Rachel Litman Flynn
, Richard C. Centore
, et al.
·
Nature
·
342
CRL4Cdt2-Mediated Destruction of the Histone Methyltransferase Set8 Prevents Premature Chromatin Compaction in S Phase
2010
·
Richard C. Centore
, Courtney G. Havens
, et al.
·
Molecular Cell
·
216
PDF
Spartan/C1orf124, a Reader of PCNA Ubiquitylation and a Regulator of UV-Induced DNA Damage Response
2012
·
Richard C. Centore
, Stephanie A. Yazinski
, et al.
·
Molecular Cell
·
139
PDF
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
2016
·
Andrew R Conery
, Richard C Centore
, et al.
·
eLife
·
125
Localization of RecA in Escherichia coli K‐12 using RecA–GFP
2005
·
Nicholas Renzette
, Nathan Gumlaw
, et al.
·
Molecular Microbiology
·
111
PDF
UvrD Limits the Number and Intensities of RecA-Green Fluorescent Protein Structures in Escherichia coli K-12
2007
·
Richard C. Centore
, Steven J. Sandler
·
Journal of Bacteriology
·
49
Direct Role for Proliferating Cell Nuclear Antigen in Substrate Recognition by the E3 Ubiquitin Ligase CRL4Cdt2
2012
·
Courtney G. Havens
, Nadia Shobnam
, et al.
·
Journal of Biological Chemistry
·
45
PDF
XthA (Exonuclease III) regulates loading of RecA onto DNA substrates in log phase Escherichia coli cells
2007
·
Richard C. Centore
, Roxane Lestini
, et al.
·
Molecular Microbiology
·
36
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
2025
·
Rishi G. Vaswani
, David S. Huang
, et al.
·
Journal of Medicinal Chemistry
·
33
Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2016
·
Andrew R. Conery
, Richard C. Centore
, et al.
·
Cancer Research
·
32
PDF
UvrD303, a Hyperhelicase Mutant That Antagonizes RecA-Dependent SOS Expression by a Mechanism That Depends on Its C Terminus
2008
·
Richard C. Centore
, Michael C. Leeson
, et al.
·
Journal of Bacteriology
·
24
Differential Requirements of Two recA Mutants for Constitutive SOS Expression in Escherichia coli K-12
2008
·
Jarukit Edward Long
, Nicholas Renzette
, et al.
·
PLoS ONE
·
18
PDF
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
2016
·
Andrew R Conery
, Richard C Centore
, et al.
·
eLife
·
13
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2023
·
Richard C. Centore
, Luis M. M. Soares
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
8
PDF
Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers
2021
·
Richard C. Centore
, Luis M. Soares
, et al.
·
Cancer Research
·
4
Pharmacokinetic profile of raxofelast, A novel antioxidant agent chemically related to alpha-Tocopherol
1995
·
R. Centore
, T. Bianco
, et al.
·
Pharmacological Research
·
4
Abstract A056: Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer
2023
·
Gabriel J Sandoval
, Richard C Centore
, et al.
·
Molecular Cancer Therapeutics
·
3
Abstract A064: Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC)
2023
·
Molly M. Wilson
, Ammar Adam
, et al.
·
Molecular Cancer Therapeutics
·
3
Selective Inhibition of the m6a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia
2024
·
Mansi Arora
, Richard Centore
, et al.
·
Blood
·
2
PDF
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025
·
Richard C Centore
, Luis MM Soares
, et al.
·
eLife
·
1
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024
·
Richard C Centore
, Luis MM Soares
, et al.
·
eLife
·
1
PDF
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024
·
Richard C. Centore
, Luis M. M. Soares
, et al.
·
eLife
·
1
Abstract 3231: Pharmacological inhibition of the m6A RNA reader, YTHDC1, as a novel approach to targeting biomolecular condensates in cancer
2024
·
Richard C. Centore
, Mark Charles
, et al.
·
Cancer Research
·
1
888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models
2022
·
Kana Ichikawa
, Ammar Adam
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Show more works
View as search
Works count:
62
Citation count:
1,607
H-index:
13
I10-index:
14
Year
Topic
Type
